

# Shenlian Extract in the Treatment of Ultrafine Particulate Matter- Aggravated Myocardial Ischemic Injury: Integrating Network Pharmacology and in vivo Pharmacological Evaluation

## Shuiqing Qu

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China. 3 School of Traditional Chinese Medicine-GDPU.

## Kai Li

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China. 3 School of Traditional Chinese Medicine-GDPU.

## Ting Yang

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China. 3 School of Traditional Chinese Medicine-GDPU.

## Yuanmin Yang

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

## Zhongyuzn Zheng

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

## Hui Liu

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China. 3 School of Traditional Chinese Medicine-GDPU.

## Xi Wang

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

## Yu Zhang

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

## Shuoqiu Deng

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

**Xiaoxin Zhu**

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

**Lina Chen**

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

**Yujie Li (✉ [yjli@icmm.ac.cn](mailto:yjli@icmm.ac.cn))**

Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China. 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

---

**Research**

**Keywords:** SL extract, Myocardial ischemic injury, Ultrafine Particle, Mechanism of action, Network 38 pharmacology, NOD-like signaling pathway

**Posted Date:** September 8th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-62327/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Shenlian Extract in the Treatment of Ultrafine Particulate Matter- aggravated Myocardial Ischemic Injury: Integrating Network Pharmacology and in vivo Pharmacological Evaluation

1 Shuiqing Qu<sup>1,2,3#</sup>, Kai Li<sup>1,2#</sup>, Ting Yang<sup>1,2</sup>, Yuanmin Yang<sup>1,2</sup>, Zhongyuzn Zheng<sup>1,2</sup>, Hui Liu<sup>1,2,3</sup>, Xi  
2 Wang<sup>1,2</sup>, Yu Zhang<sup>1,2</sup>, Shuoqiu Deng<sup>1,2</sup>, Xiaoxin Zhu<sup>1\*</sup>, Lina Chen<sup>1,2\*</sup>, Yujie Li<sup>1,2\*</sup>

## 3 Abstract

4 Background: Air pollution is a growing public health burden associated with several negative health  
5 effects, especially cardiovascular disease. Shenlian extract (SL), a traditional Chinese medicine, has the  
6 effects of clearing heat-toxin and promoting blood circulation for removing blood stasis, and it has long  
7 been used to treat cardiovascular diseases and atherosclerosis. This study explored the underlying action  
8 mechanism of SL against ultrafine particle-induced myocardial ischemic injury (UFP-MI) through network  
9 pharmacology prediction and experimental verification.

10 Methods: Male Sprague-Dawley rats with UFP-MI were pre-treated with SL intragastrically for 7 days, all  
11 the animals were randomly divided into five groups: Sham, Model (UFP+MI), SLL( 31.08mg/ kg-d) + UFP+  
12 MI, SLM (62.16 mg/ kg-d) + UFP+MI, and SLH (124.32 mg/ kg-d) + UFP+ MI. SL or saline was  
13 administrated 7 days before UFP instillation (100 µg/kg), followed by 24 h of ischemia. Inflammatory  
14 cytokine detection and histopathological analysis were performed to assess the protective effects of SL. For  
15 the mechanism study, differentially expressed genes were identified in UFP-MI rats treated with SL  
16 through transcriptomic analysis. Subsequently, in combination with network pharmacology, potential  
17 pathways involved in the effects of SL treatment were identified using the Internet-based Computation  
18 Platform ([www.tcmip.cn](http://www.tcmip.cn)) and Cytoscape 3.6.0. Further validation experiments were performed to reveal  
19 the mechanism of the therapeutic effects of SL on UFP-MI.

20 Results: In pharmacodynamics experiments, SL significantly suppressed inflammatory cell infiltration into  
21 myocardial tissue and exhibited significant anti-inflammatory activity. Transcriptomic analysis revealed  
22 that the differentially expressed genes after SL treatment had significant anti-inflammatory,  
23 immunomodulatory, and anti-viral activities. Network pharmacology analysis illustrated that the targets  
24 of SL participate in the inflammatory response, apoptotic process, innate immune response, platelet  
25 activation, and other processes. By combining transcriptomic and network pharmacology data, we found  
26 that SL may exert anti-inflammatory effects by acting on the NOD-like signaling pathway to regulate  
27 immune response activation and inhibit systemic inflammation. Verification experiments revealed that SL  
28 suppressed NLRP3 inflammasome active and inflammasomes are cytosolic protein complexes that  
29 stimulate the activation of Caspase-1, which in turn induces the secretion of the inflammatory cytokines  
30 Interleukin-1 (IL-1), Interleukin-18(IL-18) and Interleukin-33(IL-33)

31 Conclusion: UFP can induce the activation of NLRP3 inflammasome, leading to the release of downstream  
32 the inflammatory cytokines, aggravate the pathological conditions of inflammatory infiltration, and  
33 further aggravate the myocardial ischemic injury. Experimental verification indicated that SL can directly  
34 inhibit the activation of NLRP3 inflammasomes in the NOD-like signaling pathway and reduce cytokines

35 release. In conclusion, our results confirmed that SL may prevent UFP-MI by acting on the NOD-like  
36 signaling pathway.

37 **Keywords:** SL extract; Myocardial ischemic injury; Ultrafine Particle; Mechanism of action; Network  
38 pharmacology; NOD-like signaling pathway

### 39 **Authors' information**

40 \* Correspondence: Yujie Li, yjli@icmm.ac.cn; Lina Chen, lichen@icmm.ac.cn; Xiaoxin Zhu,  
41 xxzhu@icmm.ac.cn

42 # These two authors contributed equally to this work

43

## 44 **content**

45	1	Background .....	4
46	2	Materials and Methods .....	5
47	2.1	Chemicals and reagents .....	5
48	2.2	Animals and treatments .....	5
49	2.3	Preparation of the UFP suspension .....	5
50	2.4	Intratracheal instillation method of the UFP suspension .....	5
51	2.5	Establishment of a rat model of myocardial ischemia .....	5
52	2.6	RNA extracting and sequencing .....	6
53	2.7	Prediction of the candidate targets of SL .....	6
54	2.8	Prediction of particulate matter and CVD targets .....	6
55	2.9	The candidate SL target network construction and enrichment analysis .....	6
56	2.10...	Construction of the interaction network of transcriptome differential genes and network targets	
57		.....	6
58	2.11	Enrichment analysis .....	6
59	2.12	Experimental validation.....	7
60	2.12.1	Western blotting .....	7
61	2.12.2	Real-time PCR.....	7

62	2.12.3	Hematoxylin & eosin staining .....	7
63	2.12.4	Observation of the myocardial ultrastructure .....	7
64	2.12.5	ELISA .....	7
65	2.12.6	Statistical analysis.....	7
66	3	Results .....	8
67	3.1	Treatment with SL improved survival and attenuated tissue damage in UFP-MII rats.....	8
68	3.2	Transcriptomic analysis of differentially expressed genes (DEGs).....	8
69	3.3	Enrichment analysis of callback genes .....	8
70	3.4	Prediction of the candidate targets of SL and particulate matter and CVD targets.....	9
71	3.5	Candidate target network construction and enrichment analysis of SL .....	9
72	3.6	Enrichment analysis and target–pathway network construction of SL for treating UFP-MII .....	9
73	3.7	Experimental validation.....	9
74	3.7.1	SL profoundly alleviates heart inflammation in rats with UFP-MI.....	10
75	3.7.2	Inhibitory effects of SL on NLRP3 inflammasome activation .....	10
76	4	Discussion.....	10
77	5	Conclusion.....	12
78		Abbreviations .....	12
79		Ethics Statement .....	12
80		Consent for publication.....	12
81		Availability of data and materials .....	12
82		Competing interests.....	12
83		Funding .....	12
84		Author Contributions.....	12
85		Acknowledgments.....	12
86		Affiliations .....	13

87	References .....	13
----	------------------	----

88

## 89 1 Background

90 Air pollution consists of a complex mixture of gases and particulate matter, and it is recognized as a major  
91 contributor to morbidity and mortality worldwide, particularly cardiovascular mortality [1-3]. According  
92 to the World Health Organization, air pollution causes an estimated 4.2 million deaths annually, and 91%  
93 of the world's population resides in regions in which the air quality does not meet World Health  
94 Organization recommendations [4]. In epidemiologic studies, hypertension, type 2 diabetes, overweight or  
95 obesity, hypertriglyceridemia, and hyperbetalipoproteinemia increased the susceptibility to the  
96 cardiovascular effects of air pollution [5].

97 To a certain extent, fine particulate matter, also known as ultrafine particles (UFPs), comprises all particles  
98 with a diameter of less than 1  $\mu\text{m}$ . UFPs in air pollutants are primary pathogenic factors because of their  
99 high numbers, and they possess a large surface area, allowing a substantial amount of toxic chemicals to  
100 be adsorbed [6, 7]. UFPs can pass through the respiratory tract to the alveoli with high efficiency. A small  
101 fraction of UFPs penetrates the alveolar-capillary barrier, permitting their distribution throughout the  
102 body via the circulatory system [8,9]. It is not completely clear when exposure to air pollution, especially  
103 UFPs, results in damage to the cardiopulmonary system.

104 There are various plausible hypothesized pathophysiological mechanisms linking exposure to air  
105 pollutants to cardiovascular disease (CVD), including systemic inflammation and oxidative stress,  
106 autonomic nervous system imbalance, and abnormal epigenetic changes. Susceptible populations with  
107 cardiometabolic risk factors might be more susceptible to the pro-inflammatory effects of air pollutants,  
108 leading to a higher prevalence of CVD [10]. Prior research indicated that long-term exposure to particulate  
109 matter can result in newly formed plaques, which can develop into fibrous fatty plaques that are prone to  
110 breakage and instability [10]. This mechanism has also been demonstrated in animal models, in which  
111 exposure to higher levels of particulate matter potentiated atherosclerosis by increasing the generation of  
112 reactive oxygen species, inducing vascular inflammation, and promoting lipid metabolism disorder and  
113 the instability of plaques [11,12]. In addition, epidemiological research illustrated that the severity of  
114 coronary artery disease on invasive coronary angiography increases with higher long-term exposure to  
115 particulate matter [13].

116 Shenlian extract (SL), a traditional Chinese medicine (TCM), carries the effects of clearing heat-toxin and  
117 promoting blood circulation for removing blood stasis, and it has long been used to treat CVD and  
118 atherosclerosis. Previous studies found that SL can effectively inhibit the formation of atherosclerotic  
119 plaques [14], maintain the stability of plaques[15], ameliorate local blood flow, and improve blood lipid  
120 levels[14]. Additionally, some studies demonstrated that SL can affect the transformation of macrophage  
121 phenotype and the secretion of M1 macrophage inflammatory factors and regulate the nuclear factor  
122 (NF)- $\kappa\text{B}$  signaling pathway to inhibit the inflammation of macrophages[16,17]. Recent research based on a  
123 model of myocardial ischemic injury (MI) in anesthetized dogs, ex vivo rat hearts, and H9c2  
124 cardiomyocytes illustrated that SL can reduce the severity of myocardial ischemia and the scope of  
125 myocardial ischemia. Meanwhile, SL can protect against myocardial ischemic injury through the NF- $\kappa\text{B}$   
126 signaling pathway [18].

127 Network pharmacology, which is based on big databases, examines signaling from the molecular level to  
128 the pathway level, and it has emerged as a useful tool for the detailed description of the action  
129 mechanisms of complicated drug systems [19]. The previous mode of "one target, one drug" has been  
130 updated to a new mode termed "network target, multi-components" [20, 21] Network pharmacology can  
131 be used to evaluate the rationality and compatibility of TCM by clarifying detailed compound-target and  
132 target-pathway networks. In the current study, we combined network pharmacology prediction and

133 experimental verification to explore the underlying action mechanism of SL in a rat model of  
134 UFP-aggravated MI (UFP-MI).

## 135 2 Materials and Methods

### 136 2.1 Chemicals and reagents

137 SL [22](Li Yu-jie, et al.,2011; Guo, et al.,2016) is a modern TCM formula. It is made from the extracts of two  
138 Chinese medicines, namely *Salvia miltiorrhiza* Bunge and *Andrographis paniculata* (Burm. f.)Nees. SL  
139 was prepared via alcohol extraction and macroporous resin enrichment and purification. SL contained 3%  
140 tanshinone II A, 38% salvianolic acid B, and 20% andrographolide, which were provided by the Chemical  
141 Laboratory of Institute of Chinese Materia Medica, Chinese Academy of Sciences (Beijing, China). Briefly,  
142 *Salvia miltiorrhiza* Bunge and *Andrographis paniculata* (Burm. f.) Nees were mixed at the ratio of 15:9,  
143 that were first extracted using ethanol followed by water.

144 All chemicals used in the study were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless  
145 specifically indicated. Diesel particulate matter was purchased from the National Institute of Standards  
146 and Technology of the United States. Its main chemical components are polycyclic aromatic hydrocarbons  
147 (PAHs) and nitro-polycyclic aromatic hydrocarbons (Nitro-PAHs), and its average particle size is  
148 approximately 0.18  $\mu\text{m}$ .

### 149 2.2 Animals and treatments

150 This study was performed according to the instructions of the Guide for the Care and Use of Laboratory  
151 Animals and the guidelines of Institute of Chinese Materia Medica Animal Research Committee. Male  
152 8-week-old SPF Sprague-Dawley rats ( $200 \pm 20$  g) were obtained from Beijing HFK Biotechnology Co., LTD.  
153 The rats were acclimated for 2–3 days under controlled temperature ( $24 \pm 2^\circ\text{C}$ ), relative humidity of  $60 \pm$   
154  $5\%$ , and a 12-h/12-h light/dark cycle, and animals were provided a normal diet and water daily for the  
155 duration of the experiments. Male Sprague-Dawley rats with UFP-MI were pre-treated with SL  
156 intragastrically for 7 days, all the animals were randomly divided into five groups: Sham, Model  
157 (UFP+MI), SLL( 31.08 mg/ kg. d) + UFP+ MI, SLM (62.16 mg/ kg. d) + UFP+MI, and SLH (124.32 mg/ kg. d)  
158 + UFP+ MI. SL or saline was administrated 7 days before UFP instillation (100  $\mu\text{g}/\text{kg}$ ), followed by 24 h of  
159 ischemia.

### 160 2.3 Preparation of the UFP suspension

161 An appropriate amount of SRM1650b powder was precisely weighed using a 1/100 000 electronic  
162 analytical balance and placed in an Eppendorf tube. The final concentration of the suspension was 1  
163 mg/mL, which was generated by adding the corresponding volume of phosphate buffer solution. After  
164 mixing, the particles were evenly distributed via ultrasound for 2 h, and the mixture frozen at  $-20^\circ\text{C}$  for  
165 storage.

### 166 2.4 Intratracheal instillation method of the UFP suspension

167 The preparations were sonicated for 30 min and vortexed immediately ( $<60$  s) prior to intratracheal  
168 instillation. Rats were anesthetized via an intraperitoneal injection. A volume of the UFP suspension (1  
169 mL/kg) was instilled intratracheally via a plastic, blunt cannula (1.20 mm gauge diameter). The same  
170 amount of PBS was instilled into the lungs of control rats.

### 171 2.5 Establishment of a rat model of myocardial ischemia

172 MII was induced by surgical ligation of the left anterior descending coronary artery (LAD) [23] (Zhang, et  
173 al., 2019). Healthy male Sprague-Dawley rats (weight, 180–220 g) were used for the studies. After  
174 anesthesia and successful endotracheal intubation, the rats were connected to a ventilator, and their chests

175 were opened at the left between the third and fourth intercostal spaces to expose the heart. The LAD was  
 176 ligated using a 5-0 silk suture that was inserted 2–3 mm below the junction between the left atrial  
 177 appendage and conus arteriosus and removed 1–2 mm below the lower margin of the left atrial  
 178 appendage. Successful ligation was verified by a color change.

## 179 2.6 RNA extracting and sequencing

180 RNA preparation, library construction, and sequencing were performed by CapitalBio Technology Co.,  
 181 LTD (Beijing, China) using their high-throughput genome sequencing platform. Briefly, flash-frozen heart  
 182 tissues samples were homogenized in TRIzol® reagent, and total RNA was generated according to the  
 183 manufacturer's protocol. The new-generation Illumina high-throughput sequencing platform was used to  
 184 perform sequence splicing and assembly to obtain single gene clusters. According to different sequencing  
 185 types and sequencing lengths, we selected the correct recipe and constructed the mRNA library.  
 186 Compared with bioinformatics-related databases, when a gene was upregulated in the model group and  
 187 downregulated in the SL group or vice versa, it was regarded as differentially expressed.

## 188 2.7 Prediction of the candidate targets of SL

189 The TCMIP database contains the ingredients of herbs and formulas from ETCM  
 190 (<http://www.ehbio.com/ETCM>) that were collected manually according to the Pharmacopoeia of the  
 191 People's Republic of China (2015 version) and other literature[24] (Xu, et al., 2019). In this study, the  
 192 corresponding targets of SL were obtained from the TCMIP V2.0 database using *Salvia miltiorrhiza* Bunge  
 193 and *Andrographis paniculata* (Burm. f.) Nees as keywords[25,26] (Cui Ru-yi, Xu Hai-yu, 2019; Zhang  
 194 Qian-tao, et al., 2019). In the target prediction function module of TCM, the two-dimensional structural  
 195 similarity of chemical components was compared with the drugs listed by The US Food and Drug  
 196 Administration, and the similarity score was obtained by the similarity measurement method defined by  
 197 the Tanimoto score[27](Xu, et al., 2019). Accordingly, the therapeutic targets in the DrugBank database of  
 198 known drugs are considered the candidate targets of the herbal ingredients with Tanimoto scores  $\geq 0.8$  for  
 199 the known drugs. We choose drug targets with similarity scores  $\geq 0.8$  as the candidate targets of SL.

## 200 2.8 Prediction of particulate matter and CVD targets

201 Known targets related to CVD were screened using diseases and disease phenotypes as keywords from  
 202 the Therapeutic Target Database (TTD, <http://systems.d-ock.unit.osit.jp/iddp/home/index>), the DisGeNET  
 203 Database (<https://www.disgenet.org/>), the DrugBank database (<https://www.drugbank.ca>), Human  
 204 Phenotype Ontology (<https://hpo.jax.org/app/>), and research articles. At the same time, the pathological  
 205 toxicological processes caused by particulate matter were searched in research articles to identify relevant  
 206 pathogenic targets.

## 207 2.9 The candidate SL target network construction and enrichment analysis

208 A target interaction (protein–protein interaction [PPI]) network was built by importing the gene names  
 209 into the public database STRING. The relation schema of targets was drawn using Cytoscape software.  
 210 Cytoscape 3.6.0 was used as a tool to visualize the PPI network. Furthermore, it supplies a basic set of  
 211 features for data integration, analysis, and visualization for complicated network analysis.

## 212 2.10 Construction of the interaction network of transcriptome differential genes and network targets

213 Using the PPI module to construct the map of the core target network through transcriptome differential  
 214 genes and network targets, the platform was set to the key core targets with values exceeding the node's  
 215 median for "Degree," "Betweenness," and "Closeness" as the therapeutic targets of SL for the treatment of  
 216 UFP-MI.

## 217 2.11 Enrichment analysis

218 Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were also  
219 performed on the target data using the Database for Annotation, Visualization, and Integrated  
220 Discovery[28] (Xie, et al.,2018). Gene Ontology enrichment analysis of biological process, molecular  
221 function, cellular component, and Kyoto Encyclopedia of Genes and Genomes pathways was performed  
222 [21] (Guo, et al., 2019). The main signaling pathways of the core targets were obtained to investigate the  
223 possible mechanism of action of SL in the treatment of UFP-MII.

## 224 **2.12 Experimental validation**

### 225 **2.12.1 Western blotting**

226 After obtaining myocardial tissue and extracting the total protein, bovine serum albumin (Sigma-Aldrich)  
227 was used as a standard to detect the protein concentration. Then, 5× sodium dodecyl  
228 sulfate-polyacrylamide gel electrophoresis loading buffer was mixed with the protein sample at a ratio of  
229 1:4 with heating for denaturation. Equal amounts of protein in each sample were resolved by sodium  
230 dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride  
231 membrane. Membranes were incubated with the primary antibody diluted with 5% bovine serum  
232 albumin-TBST at 4°C overnight. After three washes with TBST buffer, the blots were incubated with the  
233 secondary antibody (Abcam, Cambridge, UK) for 1 h at room temperature.  $\beta$ -actin was used as the  
234 internal reference protein. An automatic chemiluminescence image analysis system was used to develop  
235 and fix the images.

### 236 **2.12.2 Real-time PCR**

237 First, the myocardial tissue of rats was snap-frozen in liquid nitrogen, ground into a powder, and  
238 homogenized under RNase-free conditions. The total RNA was extracted from myocardial tissues using  
239 TRIzol reagent, and then RNA isolation and real-time PCR assay were conducted following the  
240 manufacturer's instructions.

### 241 **2.12.3 Hematoxylin & eosin staining**

242 Myocardial tissue samples were fixed in 10% formalin for 24 h and paraffin-embedded, and a microtome  
243 (Leica, Germany) was used to prepare 5- $\mu$ m-thick sections. After drying overnight at 40°C, the sections  
244 were stained with hematoxylin & eosin.

### 245 **2.12.4 Observation of the myocardial ultrastructure**

246 The rat myocardial tissue was extracted, and a 1 mm<sup>3</sup> section of tissue in the left ventricular anterior wall  
247 was taken at ligature 3 mm toward the apical direction, placed in 2.5% glutaraldehyde for pre-fixation for  
248 2–4 h, rinsed with 0.1 M phosphate buffered saline, subjected to gradient dehydration, soaked, embedded,  
249 sliced using an ultrathin microtome (to approximately 60–80 nm), and finally double-stained with 2%  
250 uranium acetate saturated aqueous solution and lead citrate. The myocardial ultrastructures were  
251 observed under an H-600 transmission electron microscope (Hitachi Ltd., Tokyo, Japan).

### 252 **2.12.5 ELISA**

253 Interleukin (IL)-1 $\alpha$ , IL-1 $\beta$ , IL-18, IL-33, IL-6, tumor necrosis factor (TNF)- $\alpha$ , and macrophage cationic  
254 peptide 1 (MCP-1) levels were measured using ELISA kits.

### 255 **2.12.6 Statistical analysis**

256 Data were presented as the mean  $\pm$  SD and analyzed using Graph Pad Prism 6 (Graph Pad Software, Inc.,  
257 La Jolla, CA, USA). Statistical analyses were performed using one-way ANOVA for group comparisons,  
258 and  $P < 0.05$  was considered statistically significant.

259

## 260 3 Results

### 261 3.1 Treatment with SL improved survival and attenuated tissue damage in UFP-MII rats

262 The results of 2, 3, 5-triphenyltetrazolium chloride staining of the hearts are presented in Figure 1.  
263 Significantly greater cardiovascular damage was observed in the UFP-MI model group than in the sham  
264 operation group, whereas cardiovascular injury was significantly alleviated in the SLL and SLM group.  
265 The corresponding quantitative data are presented in Figure 1A, B.

266 The ultrastructure of rat myocardial tissue was observed via transmission electron microscopy (Figure 1C).  
267 Animals in the UFP-MI model group exhibited swelling of cardiac muscle myofilaments, mitochondrial  
268 swelling, the disappearance of mitochondrial cristae, and vacant areas. After treatment, the cellularity of  
269 myofilament sarcomeres was improved, and other observations included a compact arrangement, a clear  
270 Z-line, and mild swelling of some mitochondria.

271 The results of hematoxylin & eosin staining illustrated that in the sham group, the myocardial cells were  
272 neatly arranged, the myocardial fibers were regularly arranged, and there was no obvious inflammatory  
273 cell infiltration. In the model group, the arrangement of myocardial fibers was obviously disordered. Part  
274 of the tissue exhibited fibrous edema, the number of myocardial fibers between the gaps was increased,  
275 and local visible connective tissue hyperplasia accompanied by inflammatory cell infiltration was present.  
276 SL treatment significantly reduced myocardial damage, myocardial fibrosis, inflammatory cell infiltration,  
277 and myocardial structure damage. It was speculated that SL may exert its effects by mediating  
278 inflammation, and its possible anti-inflammatory mechanism was explored using transcriptomics and  
279 network pharmacology.

### 280 3.2 Transcriptomic analysis of differentially expressed genes (DEGs)

281 To address the system-wide mechanism of the effects of SL in UFP-MII rats, we performed transcriptomic  
282 analysis of myocardial tissue. We identified 778 DEGs in the model group, including 448 upregulated and  
283 330 downregulated genes. Conversely, 337 DEGs were identified in the SL group, including 257  
284 upregulated and 80 downregulated genes. By comparing the DEGs between the model and SL groups, the  
285 expression of 140 downregulated genes and 46 upregulated genes in the model group were altered by SL  
286 treatment (which we termed callback genes). The expression of most DEGs returned to normal, whereas a  
287 few genes remained upregulated.

### 288 3.3 Enrichment analysis of callback genes

289 Next, the interaction relationships among the 186 callback genes were identified using STRING, and these  
290 genes were subsequently analyzed using ClusterONE of Cytoscape 3.6.0 (as presented in Figure 2).  
291 Callback genes were mainly divided into three clusters. Cluster 1 genes were mainly involved in the  
292 biological processes of cell cycle, cell division, proliferation, and apoptosis. Cluster 2 genes were mainly  
293 enriched for innate immunity, type I interferon regulation, inflammatory response, and response to virus.  
294 Cluster 3 was enriched for a large number of inflammatory factors, such as C-C motif chemokine ligand 20  
295 (CCL20), C-X-C motif chemokine ligand 10(CXCL10), and inflammatory cytokine interleukin-6 (IL-6), the  
296 biological process of which are mainly related to inflammation, immune regulation, response to  
297 lipopolysaccharide, and chemokines.

298 An analysis of callback genes also confirmed that SL had significant anti-inflammatory,  
299 immunomodulatory, and anti-viral effects. To further explore the potential anti-inflammatory and  
300 immunoregulatory mechanisms of SL in the treatment of UFP-MII, we first performed transcriptome  
301 sequencing and then searched for drug targets related to SL and disease targets related to particulate  
302 matter and CVD using network pharmacology.

### 303 3.4 Prediction of the candidate targets of SL and particulate matter and CVD targets

304 In the TCMIP V2.0 target prediction and functional analysis, using a similarity score of  $\geq 0.8$ , 261 potential  
305 targets of the chemical components of *Salvia miltiorrhiza Bunge* and 117 potential targets of *Andrographis*  
306 *paniculata (Burm. f.) Nees* were obtained. After eliminating the repeated targets, 283 potential targets of SL  
307 were obtained. Regarding CVD genes were collected from TTD (2398 genes), DisGeNET (3240 genes),  
308 HPO (1018 genes), and pathogenic targets associated with CVD and particulate matter from research  
309 articles (509 genes), a total of 778 DEGs were identified in the transcriptome study. Finally, we selected  
310 data from research articles and transcriptome experiments to further construction a network based on  
311 their high reliability, and the number of genes was similar to that of drug targets. After eliminate the  
312 repeated targets, we obtained 1275 disease targets.

### 313 3.5 Candidate target network construction and enrichment analysis of SL

314 After constructing the database targets network diagram of SL, we explored its pharmacodynamics  
315 mechanism. The network consisted of 143 nodes and 1048 edges. Combined with the analysis function of  
316 the Cytoscape 3.6.0 ClusterONE module, the network was mainly divided into six clusters ( $P \leq 0.05$ ). Then,  
317 we used BINGO to perform functional module analysis, and the results are presented in Figure 3. The  
318 biological function of cluster 1 was mainly involved in ATP biosynthesis and aerobic respiration. Cluster 2  
319 was mainly enriched for cellular response to histamine, GABA-gated chloride ion channel activity, and ion  
320 transport. Cluster 3 genes were mainly involved in protein hydroxylation and procollagen-proline  
321 dioxygenase activity. Cluster 4 genes mainly regulated inflammatory response, apoptotic process, innate  
322 immune response, and platelet activation. The biological functions of cluster 5 were mainly regulation of  
323 hormone secretion. Cluster 6 was enriched for the regulation of coagulation.

### 324 3.6 Enrichment analysis and target-pathway network construction of SL for treating UFP-MII

325 The targets map of the core network of the candidate targets of SL and disease targets were constructed  
326 using PPI modules. By calculating the topological characteristic values of the nodes, screening, and  
327 assessing key hub node network targets, we obtained 93 core targets, including 30 genes identified in our  
328 transcriptome experiments (Figure 4). In the pathway enrichment analysis of the 93 core targets (Figure 4B,  
329 4C), the results revealed their significant involvement in inflammatory and immune pathways, respiratory  
330 diseases, infectious diseases, and cardiovascular regulation. Among them, inflammatory immune  
331 pathways were mainly enriched for the Toll-like receptor signaling pathway, TNF signaling pathway,  
332 chemokine signaling pathway, NOD-like receptor signaling pathway, NF- $\kappa$ B signaling pathway,  
333 RIG-I-like receptor signaling pathway, and complement and coagulation cascades. NOD-like and  
334 RIG-I-like receptor signaling pathways were mainly involved in the regulation of the immune system  
335 (Figure 4E). A single enrichment analysis of 30 transcriptome genes among core targets revealed that these  
336 targets were mainly involved in two functional processes, namely cell cycle division and proliferation and  
337 immune regulation (Figure 4D).

338 Prolonged inflammation has been recognized as an underlying mechanism for many chronic diseases  
339 including cancer and CVD. Air pollution represents one of the most well-known causes of prolonged  
340 inflammation, and it eventually leads to innate immune system hyperactivation. The network enrichment  
341 analysis revealed that the core targets of SL in UFP-MI were also mainly the regulation of inflammation  
342 and immunity. Further transcriptomic analyses revealed that SL may exert anti-inflammatory effects by  
343 acting on the NOD-like signaling pathway to regulate immune response activation and inhibit systemic  
344 inflammatory development. Next, we used a variety of experimental methods to test this hypothesis.

### 345 3.7 Experimental validation

### 346 3.7.1 SL profoundly alleviates heart inflammation in rats with UFP-MI

347 Compared with the findings in the sham group, serum tumor necrosis factor (TNF- $\alpha$ ) level was  
 348 unchanged in the model group. However, IL-6, and monocyte chemoattractant protein-1(MCP-1) levels  
 349 were significantly reduced in the model group. Compared with the findings in model group, serum  
 350 TNF- $\alpha$ , IL-6, and MCP-1 levels in rats were significantly reduced by SL treatment. In addition, we found  
 351 that the serum levels of IL-1 $\alpha$ , IL-18, and IL-33 were all significantly increased in the model group, and the  
 352 upregulation of IL-1 $\alpha$ , IL-1 $\beta$ , IL-18, and IL-33 was reversed by SL treatment, as shown in Figure 5.  
 353 Together, these data demonstrated that SL profoundly alleviated heart inflammation in rats with UFP-MI.

### 354 3.7.2 Inhibitory effects of SL on NLRP3 inflammasome activation

355 The expression of NLRP3 (NLR family pyrin domain containing 3), ASC (PYD and CARD domain  
 356 containing), and Caspase-1 in rat myocardial tissue was detected using Western blotting to investigate the  
 357 mechanism of action of SL against UFP-MI. As presented in Figure 6, the NLRP3 inflammasome was  
 358 activated in the model group. Compared with the model group findings, NLRP3, ASC, and caspase-1  
 359 expression in myocardial tissue was significantly reduced by SL treatment. Meanwhile, the mRNA levels  
 360 of NLRP3, ASC, and caspase-1 in rat myocardial tissue were significantly lower in the SL group than in the  
 361 model group.

## 362 4 Discussion

363 The components of particulate matter are complex, and some toxic components reported in the literature  
 364 mainly include chemical (e.g., polycyclic aromatic hydrocarbons, heavy metals), and biological  
 365 components (e.g., bacteria, fungi, viruses, pollens, other microorganisms and their fragments) [29]. The  
 366 current findings [30] indicate that fine Particles as foreign particles in the body can trigger inflammatory  
 367 responses in affected organs. Alveolar macrophages or epithelial cells exposed to airborne particles release  
 368 pro-inflammatory mediators and elevate circulating levels of TNF- $\alpha$ , IL-8, and IL-6, consistent with the  
 369 possibility that the release of cytokines can trigger and sustain a state of mild systemic inflammation [31,  
 370 32]. Exposure to diesel exhaust particulate matter results in a markedly different response pattern. After  
 371 exposure to a lower total dose for 6–18, neutrophilia, lymphocytosis, and mastocytosis were clearly  
 372 present, resulting in bronchial mucosal damage, widespread inflammation, and adverse cardiovascular  
 373 consequences [33]. The biological components of particulate matter, because of their specific ligand  
 374 characteristics, have a unique “advantage” in activating the immune system and triggering an  
 375 inflammatory response. The cell walls of gram-negative bacteria contain endotoxins (lipopolysaccharide)  
 376 that contribute to the inflammatory effects of both coarse and fine particle air pollution [34]. Endotoxins  
 377 can also stimulate localized or systemic inflammation via the activation of pattern recognition receptors  
 378 [35]. Several studies reported that the biological and chemical components of particulate matter have  
 379 synergistic pro-inflammatory effects [36-40]. Some researchers have proven that particulate matter is a key  
 380 cause of cardiovascular morbidity and mortality [41]. Animal experiments have also confirmed that  
 381 particulate matter exposure triggers inflammation and oxidative stress, which may cause lung and heart  
 382 injure [42, 43]. The potential pathophysiological mechanisms include inflammatory dysfunction, oxidative  
 383 stress, abnormal activation of the hemostatic system, and disturbance of the autonomic nervous system  
 384 [44-46]. Inflammation plays an important role in the development of chronic diseases [47]. Strong evidence  
 385 of the association of particulate exposure with heart rate variability and systemic inflammation has been  
 386 published [48].

387 The intracellular pattern recognition NOD receptor family member NLRP3 may be a key molecule that  
 388 senses particulate matter-induced damage signals and triggers the inflammatory response [49,50]. NLRP3  
 389 can instantly activate innate immune cells to respond to dangerous and pathogen-associated molecules  
 390 [51,52]. After NLRP3 is activated, the apoptosis-related particle proteins ASC and caspase-1 constitute the  
 391 NLRP3 inflammasome, triggering the caspase-1-mediated release of IL-1 $\beta$ , IL-18, and IL-33 and initiating  
 392 the inflammatory response [53].

393 Previous studies revealed that SL had significant inhibitory effects on IL-1 and IL-6 expression. SL can  
394 inhibit the inflammatory response of macrophages, and its mechanism may be related to an influence on  
395 the phenotypic transformation of macrophages, the secretion of M1 inflammatory factors, and activation  
396 of the NF- $\kappa$ B signaling pathway in macrophages [16,17, 18]. Another study reported that SL can  
397 significantly improve the imbalance of pro-inflammatory and pro-resolving mediators during  
398 atherosclerotic inflammation [54]. In addition, a number of studies found that *Salvia miltiorrhiza* Bunge [26,  
399 27] and *Andrographis paniculata* (Burm. f.) Nees [55, 56, 57] had significant effects on inflammation and  
400 immune regulation.

401 Pharmacodynamic experiments proved that SL could effectively treat myocardial injury caused by UFPs  
402 and significantly improve the pathological state of the inflammatory infiltration of myocardial tissue. This  
403 indicates that SL can be used to treat particulate matter-induced myocardial ischemic damage; however,  
404 because of the “multi-component” and “multi-target” features of TCMs, it is difficult to study the  
405 mechanism of action using traditional methods. Therefore, we first conducted transcriptomic analysis of  
406 heart tissues before and after treatment and then added network pharmacology to gain insight into the  
407 pharmacological mechanism of SL in the treatment of UFP-MII. Functional enrichments of callback genes  
408 indicated that SL had significant anti-inflammatory, immunomodulatory, and anti-viral effects. Using  
409 network pharmacology to retrieve the drug targets of SL, the biological function enrichment analysis  
410 found that SL influenced the inflammatory response, apoptotic process, innate immune response, and  
411 platelet activation. Finally, we combined the transcriptomic results and network pharmacology data to  
412 further explore the potential anti-inflammatory mechanism of SL. The PPI network map of the candidate  
413 targets of SL and disease targets was constructed, and the core targets were selected. In total, 30 DEGs  
414 were identified among the core targets, and enrichment analysis of these genes revealed their involvement  
415 in regulation of the immune system. Pathway enrichment analysis of all core targets uncovered a large  
416 number of inflammation- and immune-related pathways. Thus, we speculated that SL may play an  
417 anti-inflammatory role by acting on the NOD-like signaling pathway to regulate immune response  
418 activation and inhibit systemic inflammatory development.

419 The NOD-like receptor family is a group of pattern recognition receptors, known to mediate the initial  
420 innate immune response to cellular injury and infection [58]. NLRP3 is a major inflammasome in CVD,  
421 and it belongs to the NOD-like receptor family. Inflammasomes are intracellular multi-protein complexes,  
422 and their components include NLRP3, ASC, and pro-caspase-1. Animal experiments [49,59, 60] illustrated  
423 that the downregulation of NLRP3, IL-1, and IL-18 can significantly reduce the area of infarction, inhibit  
424 NLRP3 inflammasome activation, and improve myocardial function. Prior studies [61] reported that  
425 particulate matter can activate the NLRP3 inflammasome. Du et al. [62] found that mononuclear  
426 macrophage (CD11c<sup>+</sup>) counts were significantly elevated in ApoE<sup>-/-</sup> mice exposed to fine particulate matter,  
427 and NLRP3, ASC, caspase-1, IL-1, and IL-18 expression was also increased. The results illustrated that fine  
428 particulate matter-related heart injury was mediated by macrophage polarization and NLRP3  
429 inflammasome activation, in line with the current study results. The current data further demonstrated  
430 that SL inhibits the activation of the NLRP3 inflammasome in myocardial tissue and alleviate cytokine  
431 release into blood, thereby reduce systemic inflammation

432 Using through the combination of transcriptomic analysis and network pharmacology, the mechanism by  
433 which SL alleviates UFP-MI was uncovered. After constructing a series of PPI network diagrams, the  
434 potential targets and pathways of SL were screened, and their reliability was verified experimentally.  
435 NLRP3 and other related proteins were not enriched in the NOD-like signaling pathway in  
436 transcriptomics, which may be related to sample loading and protein sensitivity. However, in later  
437 validation experiments, the expression of NLRP3-related proteins was significantly changed by SL  
438 treatment. At present, only in vivo experiments have been conducted, and the corresponding verification  
439 will be conducted in the later stage of in vitro experimentation.

440 Further analysis of the mechanism of action demonstrated that the effects of SL are closely related to the  
441 RIG-I-like receptor signaling pathway, which is also a pattern recognition receptor. In addition, a large

442 number of genes involved in the regulation of this pathway were enriched in the transcriptome, which  
443 will also be verified by experiments in the later stage.

## 444 **5 Conclusion**

445 UFP can induce the activation of NLRP3 inflammasome, leading to the release of downstream the  
446 inflammatory cytokines, aggravate the pathological conditions of inflammatory infiltration, and further  
447 aggravate the myocardial ischemic injury. Experimental verification demonstrated that SL can directly  
448 inhibit the activation of the NLRP3 inflammasome in the NOD-like signaling pathway and reduce the  
449 release of IL-1 family cytokines. In conclusion, our results confirm that SL may prevent UFP-MI by acting  
450 on the NOD-like signaling pathway.

## 451 **Abbreviations**

452 SL: Shenlian extract ; UFP-MI: ultrafine particle-induced myocardial ischemic injury; CVD: cardiovascular  
453 disease; MI: ischemic injury; PAHs: polycyclic aromatic hydrocarbons; Nitro-PAHs: nitro-polycyclic  
454 aromatic hydrocarbons; LAD: left anterior descending coronary artery; PPI: protein-protein interaction;  
455 IL-1 $\alpha$ : Interleukin-1 $\alpha$ ; IL-1 $\beta$ : Interleukin-1 $\beta$ ; IL-18: Interleukin-18; Interleukin-33: IL-33; IL-6: interleukin-6;  
456 TNF- $\alpha$ : tumor necrosis factor- $\alpha$ ; MCP-1: macrophage cationic peptide 1; DEGs differentially expressed  
457 genes; NLRP3: NLR family pyrin domain containing 3; CCL20: C-C motif chemokine ligand 20; CXCL10:  
458 C-X-C motif chemokine ligand 10.

## 459 **Ethics Statement**

460 All animals received human care throughout the experiments and the study protocols were approved by  
461 the Committee on the Use of Live Animals in Teaching and Research (CULATR). This study was  
462 performed according to the instructions of the Guide for the Care and Use of Laboratory Animals and the  
463 guidelines of Institute of Chinese Materia Medica Animal Research Committee.

## 464 **Consent for publication**

465 Not applicable

## 466 **Availability of data and materials**

467 All data generated or analysed during this study are included in this published article and its  
468 supplementary information files.

## 469 **Competing interests**

470 The authors declare that no competing interests.

## 471 **Funding**

472 This study was supported by the National Natural Science Foundation of China (No. 81673640, 81841001  
473 and 81803814), Major National Science and Technology Program of China for Innovative Drug  
474 (2017ZX09301012002, 2017ZX09101002-001-001-3).

## 475 **Author Contributions**

476 SQ contributed to the acquisition of data, the analysis and interpretation of the data and drafting of the  
477 work. KL, YY, TY, ZZ, HL, XW, YZ, SD conducted the experiments and analyzed data. YL, XZ, LC design  
478 of the study and revising the work.

## 479 **Acknowledgments**

480 Special thanks to Dr. Yanqiong Zhang for guidance and help in data analysis.

#### 481 **Affiliations**

482 1 Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing China.

483 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing China.

484 3 School of Traditional Chinese Medicine, GDPU.


#### 485 **References**

- 486 1. Zavala, J.; Freedman, A.N.; Szilagy, J.T., et al. New Approach Methods to Evaluate Health Risks of Air  
487 Pollutants: Critical Design Considerations for In Vitro Exposure Testing. *Int J Environ Res Public Health*  
488 2020, 17. doi: 10.3390/ijerph17062124.
- 489 2. Miller, M.R.; Newby, D.E. Air pollution and cardiovascular disease: car sick. *Cardiovasc. Res.* 2020, 116,  
490 279-294. doi:10.1093/cvr/cvz228.
- 491 3. Raza, W.; Forsberg, B.; Johansson, C.; Sommar, J.N. Air pollution as a risk factor in health impact  
492 assessments of a travel mode shift towards cycling. *Glob Health Action* 2018, 11, 1429081. doi:  
493 10.1080/16549716.2018.1429081.
- 494 4. Kotsyfakis, M.; Patelarou, E. MicroRNAs as biomarkers of harmful environmental and occupational  
495 exposures: a systematic review. *Biomarkers* 2019, 24, 623-630. doi: 10.1080/1354750X.2019.1652348.
- 496 5. Zhang, Y.; Wang, S.G.; Ma, Y.X., et al. Association between Ambient Air Pollution and Hospital  
497 Emergency Admissions for Respiratory and Cardiovascular Diseases in Beijing: a Time Series Study.  
498 *Biomed. Environ. Sci.* 2015, 28, 352-363. doi: 10.3967/bes2015.049.
- 499 6. Kwon, H.S.; Ryu, M.H.; Carlsten, C. Ultrafine particles: unique physicochemical properties relevant to  
500 health and disease. *Exp. Mol. Med.* 2020, 52, 318-328. doi: 10.1038/s12276-020-0405-1.
- 501 7. Khan, K.M.; Weigel, M.M.; Yonts, S.; Rohlman, D.; Armijos, R. Residential exposure to urban traffic is  
502 associated with the poorer neurobehavioral health of Ecuadorian schoolchildren. *Neurotoxicology* 2019,  
503 73, 31-39. doi: 10.1016/j.neuro.2019.02.018.
- 504 8. Miller, M.R.; Raftis, J.B.; Langrish, J.P., et al. Inhaled Nanoparticles Accumulate at Sites of Vascular  
505 Disease. *ACS Nano* 2017, 11, 4542-4552. doi: 10.1021/acsnano.6b08551.
- 506 9. Lee, H.C.; Lin, T.H. Air Pollution Particular Matter and Atherosclerosis. *Acta Cardiol Sin* 2017, 33,  
507 646-647. doi: 10.6515/ACS20170615A.
- 508 10. Yang, S.; Lee, S.P.; Park, J.B., et al. PM2.5 concentration in the ambient air is a risk factor for the  
509 development of high-risk coronary plaques. *Eur Heart J Cardiovasc Imaging* 2019, 20, 1355-1364. doi:  
510 10.1093/ehjci/jez209.
- 511 11. Zhao, J.; Mi, X.; Zhao, L., et al. Validation of PM2.5 model particle through physicochemical evaluation  
512 and atherosclerotic plaque formation in ApoE<sup>-/-</sup> mice. *Ecotoxicol. Environ. Saf.* 2020, 192, 110308.  
513 10.1016/j.ecoenv.2020.110308.
- 514 12. Rao, X.; Zhong, J.; Maiseyeu, A., et al. CD36-dependent 7-ketocholesterol accumulation in macrophages  
515 mediates progression of atherosclerosis in response to chronic air pollution exposure. *Circ. Res.* 2014, 115,  
516 770-780. doi: 10.1161/CIRCRESAHA.115.304666.
- 517 13. Hartiala, J.; Breton, C.V.; Tang, W.H., et al. Ambient Air Pollution Is Associated With the Severity of  
518 Coronary Atherosclerosis and Incident Myocardial Infarction in Patients Undergoing Elective Cardiac  
519 Evaluation. *J Am Heart Assoc* 2016, 5. doi: 10.1161/JAHA.116.003947.

- 520 14. Guo, Y.; Liu, X.C.; Wang, Y.J., et al. Effects of Shenlian extract on experimental atherosclerosis in  
521 ApoE-deficient mice based on ultrasound biomicroscopy. *BMC Complement Altern Med* 2016, 16, 469.  
522 doi: 10.1186/s12906-016-1449-6.
- 523 15. Li Yu-jie, Ruan Cong-xiao, Yang Qing, et al. Establishment of vulnerable plaque model by mast cell  
524 activation in adventitia and evaluation of effectiveness of intervention of Shenlian tablet. *Acta*  
525 *Pharmaceutica Sinica*. 2016. 51(08): 1263-1270.
- 526 16. Liu Si-si, Li Qi, Sun Li-dong, et al. Effects of Shenlian Extract on Lipopolysaccharide-induced  
527 Inflammation of Macrophages. *Chinese Journal of Experimental Traditional Medical Formulae*. 2017.  
528 23(10): 85-91.
- 529 17. Zhou Bing-bing, Li Yu-jie, Li Qi et al. Effect on M1 macrophages of Shenlian extracts. *China Journal of*  
530 *Chinese Materia Medica*. 2014. 39(11): 2086-2090.
- 531 18. Guo, Y.; Yang, Q.; Weng, X.G., et al. Shenlian Extract Against Myocardial Injury Induced by Ischemia  
532 Through the Regulation of NF- $\kappa$ B/I $\kappa$ B Signaling Axis. *Front Pharmacol* 2020, 11, 134. doi:  
533 10.3389/fphar.2020.00134.
- 534 19. Chen, Y.; Kern, T.S.; Kiser, P.D.; Palczewski, K. Eyes on systems pharmacology. *Pharmacol. Res.* 2016,  
535 114, 39-41. doi: 10.1016/j.phrs.2016.09.026.
- 536 20. Li, S.; Zhang, B. Traditional Chinese medicine network pharmacology: theory, methodology and  
537 application. *Chin J Nat Med* 2013, 11, 110-120. doi: 10.1016/S1875-5364(13)60037-0.
- 538 21. Guo, W.; Huang, J.; Wang, N., et al. Integrating Network Pharmacology and Pharmacological  
539 Evaluation for Deciphering the Action Mechanism of Herbal Formula Zuojin Pill in Suppressing  
540 Hepatocellular Carcinoma. *Front Pharmacol* 2019, 10, 1185. doi: 10.3389/fphar.2019.01185.
- 541 22. Li Yu-jie, Zhu Xiao-xin, Yang qing, et al.(2011) Effect of *Salviae Miltiorhize Radix* and *Andrographitis*  
542 *Herba* extracts on vessel pathological changes and lipid metabolism in atherosclerosis rabbits. *Chinese*  
543 *Traditional and Herbal Drugs*. 2011. 42(04): 760-764.
- 544 23. Zhang, X.; Guan, J.; Guo, M., et al. Rho GTPase-activating protein 1 promotes apoptosis of myocardial  
545 cells in an ischemic cardiomyopathy model. *Kardiol Pol* 2019, 77, 1163-1169. doi: 10.33963/KP.15040.
- 546 24. Xu, H.Y.; Zhang, Y.Q.; Liu, Z.M., et al. ETCM: an encyclopaedia of traditional Chinese medicine. *Nucleic*  
547 *Acids Res.* 2019, 47, D976-976D982. doi: 10.1093/nar/gky987.
- 548 25. Cui Ru-yi, Xu Hai-yu. Study on quality markers of ginseng acting on heart failure based on TCMIP V2.0.  
549 *Chinese Traditional and Herbal Drugs*. 2019. 50(19): 4628-4633.
- 550 26. Zhang Qian-tao, Hou min-na, Peng Xiu-juan, et al. The predictive analysis of action mechanism for  
551 classic TCM excellent prescriptions of Danggui Buxue decoction on diabetes with TCMIP. *Chinese*  
552 *Pharmacological Bulletin*. 2019. 35(09): 1314-1319.
- 553 27. Xu, H.Y.; Liu, Z.M.; Fu, Y., et al. Exploiture and application of an internet-based Computation Platform  
554 for Integrative Pharmacology of Traditional Chinese Medicine. *Zhongguo Zhong Yao Za Zhi* 2017, 42,  
555 3633-3638. doi: 10.19540/j.cnki.cjcmm.2017.0141.
- 556 28. Xie, G.; Peng, W.; Li, P., et al. A Network Pharmacology Analysis to Explore the Effect of *Astragali*  
557 *Radix-Radix Angelica Sinensis* on Traumatic Brain Injury. *Biomed Res Int* 2018, 2018, 3951783. doi:  
558 10.1155/2018/3951783.
- 559 29. Wang Zhi-hong. Studies on the pro-inflammatory effects of atmospheric particulate matter biochemical  
560 components. *Chemical Enterprise Management*. 2020. (12): 19-20.
- 561 30. Yoshizaki, K.; Brito, J.M.; Toledo, A.C., et al. Subchronic effects of nasally instilled diesel exhaust  
562 particulates on the nasal and airway epithelia in mice. *Inhal Toxicol* 2010, 22, 610-617. doi:  
563 10.3109/08958371003621633.

- 564 31. Pope, C.A.; Bhatnagar, A.; McCracken, J.P.; Abplanalp, W.; Conklin, D.J.; O'Toole, T. Exposure to Fine  
565 Particulate Air Pollution Is Associated With Endothelial Injury and Systemic Inflammation. *Circ. Res.*  
566 2016, 119, 1204-1214. doi: 10.1161/CIRCRESAHA.116.309279.
- 567 32. Siponen, T.; Yli-Tuomi, T.; Aurela, M., et al. Source-specific fine particulate air pollution and systemic  
568 inflammation in ischaemic heart disease patients. *Occup Environ Med* 2015, 72, 277-283. doi:  
569 10.1136/oemed-2014-102240.
- 570 33. Sehlstedt, M.; Dove, R.; Boman, C., et al. Antioxidant airway responses following experimental  
571 exposure to wood smoke in man. *Part Fibre Toxicol* 2010, 7, 21. doi: 10.1186/1743-8977-7-21.
- 572 34. Behbod, B.; Urch, B.; Speck, M., et al. Endotoxin in concentrated coarse and fine ambient particles  
573 induces acute systemic inflammation in controlled human exposures. *Occup Environ Med* 2013, 70,  
574 761-767. doi: 10.1136/oemed-2013-101498.
- 575 35. Mani, V.; Weber, T.E.; Baumgard, L.H.; Gabler, N.K. Growth and Development Symposium: Endotoxin,  
576 inflammation, and intestinal function in livestock. *J. Anim. Sci.* 2012, 90, 1452-1465. doi:  
577 10.2527/jas.2011-4627.
- 578 36. Liu, D.; Mariman, R.; Gerlofs-Nijland, M.E., et al. Microbiome composition of airborne particulate  
579 matter from livestock farms and their effect on innate immune receptors and cells. *Sci. Total Environ.* 2019,  
580 688, 1298-1307. doi: 10.1016/j.scitotenv.2019.06.217.
- 581 37. Liu, Q.; Baumgartner, J.; Schauer, J.J. Source Apportionment of Fine-Particle, Water-Soluble Organic  
582 Nitrogen and Its Association with the Inflammatory Potential of Lung Epithelial Cells. *Environ. Sci.*  
583 *Technol.* 2019, 53, 9845-9854. doi: 10.1021/acs.est.9b02523.
- 584 38. Brinchmann, B.C.; Skuland, T.; Rambøl, M.H., et al. Lipophilic components of diesel exhaust particles  
585 induce pro-inflammatory responses in human endothelial cells through AhR dependent pathway(s). *Part*  
586 *Fibre Toxicol* 2018, 15, 21. doi: 10.1186/s12989-018-0257-1.
- 587 39. Baulig, A.; Singh, S.; Marchand, A., et al. Role of Paris PM(2.5) components in the pro-inflammatory  
588 response induced in airway epithelial cells. *Toxicology* 2009, 261, 126-135. doi: 10.1016/j.tox.2009.05.007.
- 589 40. Xiao, G.G.; Wang, M.; Li, N.; Loo, J.A.; Nel, A.E. Use of proteomics to demonstrate a hierarchical  
590 oxidative stress response to diesel exhaust particle chemicals in a macrophage cell line. *J. Biol. Chem.* 2003,  
591 278, 50781-50790. doi: 10.1074/jbc.M306423200.
- 592 41. Brook, R.D.; Rajagopalan, S.; Pope, C.A., et al. Particulate matter air pollution and cardiovascular  
593 disease: An update to the scientific statement from the American Heart Association. *Circulation* 2010, 121,  
594 2331-2378. doi: 10.1161/CIR.0b013e3181d8e3e1.
- 595 42. Jiang, S.; Bo, L.; Du X, et al. CARD9-mediated ambient PM2.5-induced pulmonary injury is associated  
596 with Th17 cell. *Toxicol. Lett.* 2017, 273, 36-43. doi: 10.1016/j.toxlet.2017.03.015.
- 597 43. Zhao, J.; Liu, C.; Bai, Y.; Wang, T.Y.; Kan, H.; Sun, Q. IKK inhibition prevents PM2.5-exacerbated cardiac  
598 injury in mice with type 2 diabetes. *J Environ Sci (China)* 2015, 31, 98-103. doi: 10.1016/j.jes.2014.10.018.
- 599 44. Feng, S., Gao, D., Liao, F., Zhou, F., and Wang, X. The health effects of ambient PM2.5 and potential  
600 mechanisms. *Ecotoxicol. Environ. Saf.* 128, 67-74. doi: 10.1016/j.ecoenv.2016.01.030
- 601 45. Wang, C.; Tu, Y.; Yu, Z.; Lu, R. PM2.5 and Cardiovascular Diseases in the Elderly: An Overview. *Int J*  
602 *Environ Res Public Health* 2015, 12, 8187-8197. doi: 10.3390/ijerph120708187.
- 603 46. Lawal, A.O. Air particulate matter induced oxidative stress and inflammation in cardiovascular disease  
604 and atherosclerosis: The role of Nrf2 and AhR-mediated pathways. *Toxicol. Lett.* 2017, 270, 88-95. doi:  
605 10.1016/j.toxlet.2017.01.017.


- 606 47. Shou, Y.; Zhu, X.; Zhu, D., et al. Ambient PM<sub>2.5</sub> chronic exposure leads to cognitive decline in mice:  
607 From pulmonary to neuronal inflammation. *Toxicol. Lett.* 2020, 331, 208-217. doi:  
608 10.1016/j.toxlet.2020.06.014.
- 609 48. Fang, S.C.; Cassidy, A.; Christiani, D.C. A systematic review of occupational exposure to particulate  
610 matter and cardiovascular disease. *Int J Environ Res Public Health* 2010, 7, 1773-1806. doi:  
611 10.3390/ijerph7041773.
- 612 49. Du X; Jiang, S.; Zeng, X., et al. Fine particulate matter-induced cardiovascular injury is associated with  
613 NLRP3 inflammasome activation in Apo E<sup>-/-</sup> mice. *Ecotoxicol. Environ. Saf.* 2019, 174, 92-99. doi:  
614 10.1016/j.ecoenv.2019.02.064.
- 615 50. Ding, S.; Wang, H.; Wang, M.; Bai, L.; Yu, P.; Wu, W. Resveratrol alleviates chronic "real-world" ambient  
616 particulate matter-induced lung inflammation and fibrosis by inhibiting NLRP3 inflammasome  
617 activation in mice. *Ecotoxicol. Environ. Saf.* 2019, 182, 109425. doi: 10.1016/j.ecoenv.2019.109425.
- 618 51. Li, H.; Zhang, S.; Li, F.; Qin, L. NLRX1 attenuates apoptosis and inflammatory responses in myocardial  
619 ischemia by inhibiting MAVS-dependent NLRP3 inflammasome activation. *Mol. Immunol.* 2016, 76,  
620 90-97. doi: 10.1016/j.molimm.2016.06.013.
- 621 52. Toldo, S.; Marchetti, C.; Mauro, A.G., et al. Inhibition of the NLRP3 inflammasome limits the  
622 inflammatory injury following myocardial ischemia-reperfusion in the mouse. *Int. J. Cardiol.* 2016, 209,  
623 215-220. doi: 10.1016/j.ijcard.2016.02.043.
- 624 53. Shi, J.; Gao, W.; Shao, F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. *Trends*  
625 *Biochem. Sci.* 2017, 42, 245-254. doi: 10.1016/j.tibs.2016.10.004.
- 626 54. Guo Y. Mechanism study of Shenlian extract on the regulation of atherosclerotic inflammation  
627 resolution. (11), 2015.
- 628 55. Lin Meng-ya, Zhang Yu-ping, Li Ya, et al. Spectra-effect relationship of anti-inflammation of *Salvia*  
629 *miltiorrhiza* extract based on gray correlation analysis. *Chinese Traditional and Herbal Drugs* 48,  
630 3447-3452. doi: 10.7501/j.issn.0253-2670.2017.16.031.
- 631 56. Wang Han, Yang Na, Tan jing, et al. Research Progress on *Salvia Miltiorrhiza* Bge of the Chemical  
632 Constituents and Their Pharmacological Effects. *Special Wild Economic Animal and Plant Research.* 2018.  
633 40(1): 48-53.
- 634 57. Yin Qing, Deng Ming-ming. Progress in research on anti-inflammatory mechanism of *Andrographolide*.  
635 *Guangdong Medical Journal.* 2014. 35(5): 786-788.
- 636 58. Tong jiao, Ge Zi-yu, Jiang Li. Progress in the study of in vivo distribution and anti-inflammatory  
637 mechanism of *andrographolide* and its derivatives. *Chinese Journal of Clinical Rational Drug Use* 2020,  
638 13, 180-181. doi: 10.15887/j.cnki.13-1389/r.2020.08.107.
- 639 59. Lamkanfi, M.; Dixit, V.M. Mechanisms and functions of inflammasomes. *Cell* 2014, 157, 1013-1022. doi:  
640 10.1016/j.cell.2014.04.007.
- 641 60. Liu, Y.; Lian, K.; Zhang, L., et al. TXNIP mediates NLRP3 inflammasome activation in cardiac  
642 microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. *Basic*  
643 *Res. Cardiol.* 2014, 109, 415. doi: 10.1007/s00395-014-0415-z.
- 644 61. van Hout GP; Arslan, F.; Pasterkamp, G.; Hoefer, I.E. Targeting danger-associated molecular patterns  
645 after myocardial infarction. *Expert Opin. Ther. Targets* 2016, 20, 223-239. doi:  
646 10.1517/14728222.2016.1088005.
- 647 62. Yan, Z.; Jin, Y.; An, Z.; Liu, Y.; Samet, J.M.; Wu, W. Inflammatory cell signaling following exposures to  
648 particulate matter and ozone. *Biochim. Biophys. Acta* 2016, 1860, 2826-2834. doi:  
649 10.1016/j.bbagen.2016.03.030.




651

652 **Figure 1.** Efficacy evaluation of Shenlian extract (SL). (a, b) Effect of SL on infarct size in the experimental  
 653 rats and the infarct rate as a percentage of the total size. Heart sections of the experimental rats stained  
 654 with 2, 3, 5-triphenyltetrazolium chloride. Normal tissue was stained red, and infarcted tissue was pale. (c)

655 Ultrastructural changes of myocardial tissue and the effect of SL treatment (left, ×2000; right, ×50,000). (d)  
 656 Myocardial histopathological changes and SL in rats (hematoxylin & eosin: left, ×200; right, ×400). \*P < 0.05,  
 657 \*\*P < 0.01, \*\*\*P < 0.001.




658  
 659 **Figure 2.** The enrichment analysis of genes altered by SL treatment following ultrafine particle-induced  
 660 myocardial ischemic injury. The green, blue, and red nodes represent clusters 1, 2, and 3, respectively, and  
 661 the pink nodes are the join points.




662

663 **Figure3.** Enrichment analysis of Shenlian extract (SL). From top to bottom and from left to right, six  
 664 clusters are respectively represented. The red triangles denote SL compound target, and the dashed boxes  
 665 denote the biological function involving the corresponding cluster targets.




666

667 **Figure 4.** Enrichment analysis and target–pathway network construction for Shenlian extract for treating  
 668 ultrafine particle-induced myocardial ischemic injury (a) Ninety-three core targets, including 30 green  
 669 genes identified by our transcriptome research. (b, c) Pathway enrichment analysis of the 93 core targets.  
 670 (d) The enrichment analysis of 30 transcriptome genes among core targets. (e) Key pathways of core target  
 671 enrichment.



672

673 **Figure 5.** Expression of inflammatory factors and NLRP3 inflammasome-associated downstream  
 674 cytokines. (a-c) The changes of inflammatory cytokine interleukin (IL)-6, tumor necrosis factor (TNF)- $\alpha$ ,  
 675 monocyte chemoattractant protein-1 (MCP)-1 levels in the serum of rats and the effects of Shenlian extract  
 676 (SL). (d-g) Quantitative reverse results of interleukin (IL)-1 $\alpha$ , IL-1 $\beta$ , IL-18, and IL-33 in the serum of rats.  
 677 \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001.




678

679 **Figure 6.** The expression of NLRP3 inflammasome. (a- d) Expression of NLRP3 inflammasome-associated  
 680 proteins in the myocardial tissue of rats (n = 3,  $\bar{x} \pm s$ ). (e-g) Expression of NLRP3 inflammasome-associated  
 681 mRNA in the myocardial tissue of rats (n = 3,  $\bar{x} \pm s$ ). \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

682

683


# Figures



**Figure 1**

Efficacy evaluation of Shenlian extract (SL). (a, b) Effect of SL on infarct size in the experimental rats and the infarct rate as a percentage of the total size. Heart sections of the experimental rats stained with 2, 3, 5-triphenyltetrazolium chloride. Normal tissue was stained red, and infarcted tissue was pale. (c)


Ultrastructural changes of myocardial tissue and the effect of SL treatment (left,  $\times 2000$ ; right,  $\times 50,000$ ).  
 (d) Myocardial histopathological changes and SL in rats (hematoxylin & eosin: left,  $\times 200$ ; right,  $\times 400$ ). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .



**Figure 2**


The enrichment analysis of genes altered by SL treatment following ultrafine particle-induced myocardial ischemic injury. The green, blue, and red nodes represent clusters 1, 2, and 3, respectively, and the pink nodes are the join points.






**Figure 4**

Enrichment analysis and target–pathway network construction for Shenlian extract for treating ultrafine particle-induced myocardial ischemic injury (a) Ninety-three core targets, including 30 green genes identified by our transcriptome research. (b, c) Pathway enrichment analysis of the 93 core targets. (d) The enrichment analysis of 30 transcriptome genes among core targets. (e) Key pathways of core target enrichment.



**Figure 5**

Expression of inflammatory factors and NLRP3 inflammasome-associated downstream cytokines. (a-c) The changes of inflammatory cytokine interleukin (IL)-6, tumor necrosis factor (TNF)- $\alpha$ , monocyte chemoattractant protein-1 (MCP)-1 levels in the serum of rats and the effects of Shenlian extract (SL). (d-g) Quantitative reverse results of interleukin (IL)-1 $\alpha$ , IL-1 $\beta$ , IL-18, and IL-33 in the serum of rats. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .



**Figure 6**

The expression of NLRP3 inflammasome. (a- d) Expression of NLRP3 inflammasome-associated proteins in the myocardial tissue of rats (n = 3,  $\bar{x} \pm s$ ). (e-g) Expression of NLRP3 inflammasome-associated mRNA in the myocardial tissue of rats (n = 3,  $\bar{x} \pm s$ ). \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.